Incyte (INCY) Profit Margin History
Historical gross, operating and net quarterly profit margin for Incyte (INCY) over the last 10 years. The current net profit margin for Incyte as of March 19, 2018 is -20.38%.
|Medical||Medical - Biomedical and Genetics||$18.272B||$1.536B|
|Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.|